Celcuity’s newly launched REVTORPYK combines strong clinical differentiation and a $754M runway with meaningful execution, tolerability, and convertible-debt risks.
Celcuity Inc. (NASDAQ: CELC) is a clinical-stage turned commercial-stage oncology biotechnology company focused on developing and commercializing targeted therapies for solid tumor indications, underpinned by a proprietary live-cell functional analysis diagnostic platform [cite: 1, 2, 3]. The company operates in the precision oncology sector, primarily targeting therapeutic gaps in hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer [cite: 1, 4].
Celcuity is undergoing an operational transition following the United States Food and Drug Administration (FDA) approval of its lead drug candidate, REVTORPYK (gedatolisib), on July 14, 2026 [cite: 1, 4]. Commercial availability of REVTORPYK in the United States commenced on September 30, 2026, marking the beginning of direct product revenue generation [cite: 4]. The company generates revenue through direct pharmaceutical sales in the United States via its commercial sales infrastructure, with prospective global expansion opportunities through strategic partnerships, licensing, and international distribution channels [cite: 1, 4].
The core products and service architecture consist of two foundational assets:
* REVTORPYK (gedatolisib): A first-in-class, intravenously administered pan-PI3K and mTOR complex (mTORC1 and mTORC2) inhibitor [cite: 5, 6, 7]. Gedatolisib was licensed globally from Pfizer Inc. in April 2021 [cite: 2, 3, 8]. It is approved for adult patients with HR+/HER2-, PIK3CA wild-type (WT) locally advanced or metastatic breast cancer whose disease progressed following at least one line of endocrine therapy [cite: 1, 4].
* CELsignia Companion Diagnostic (CDx) Platform: A proprietary functional cellular analysis platform that measures dynamic pathway signaling in live tumor cells extracted from patient tissue samples [cite: 2, 3, 9]. Unlike static genomic sequencing, CELsignia evaluates real-time functional pathway activation, enabling the identification of oncogenic driver mechanisms that static genomic tests miss [cite: 2, 3, 9].
Celcuity’s primary customers comprise medical oncologists, regional and national healthcare networks, comprehensive cancer treatment centers, and specialty pharmacy distributors across North America and select international jurisdictions [cite: 4, 10]. Its most critical end market is the post-CDK4/6 inhibitor second-line (2L+) treatment landscape for HR+/HER2- advanced breast cancer, an addressable patient segment encompassing tens of thousands of individuals annually in the United States alone [cite: 1, 4].
Oncologists select REVTORPYK over competitive single-node therapies—such as PI3K$\alpha$-selective inhibitors or AKT inhibitors—due to its multi-node mechanism of action [cite: 6, 7, 11]. Single-node inhibitors frequently trigger compensatory bypass pathways that drive therapeutic resistance [cite: 7, 11]. REVTORPYK concurrently suppresses all four class I PI3K isoforms alongside mTORC1 and mTORC2, blocking feedback reactivation loops [cite: 6, 7, 11, 12]. Clinically, this multi-target profile translates to efficacy—demonstrating a 76% reduction in the risk of disease progression or death in PIK3CA wild-type patients compared to standard-of-care fulvestrant—while maintaining a manageable toxicity profile with significantly lower rates of severe hyperglycemia relative to older class members [cite: 4, 6, 7, 13].
Celcuity's long-term valuation and growth narrative depend on commercial execution with REVTORPYK in 2L+ HR+/HER2- metastatic breast cancer, successful label expansion into additional lines of therapy, and pipeline expansion leveraging the CELsignia platform [cite: 1, 2, 3, 4].
REVTORPYK (gedatolisib) is a small molecule delivered via weekly intravenous infusions at a recommended dose of 180 mg administered weekly for 3 weeks of a 4-week cycle [cite: 7, 12, 14]. While competitor compounds selectively target single components of the PI3K/AKT/mTOR (PAM) network—such as alpelisib (Piqray) and inavolisib (Itovebi) targeting PI3K$\alpha$, capivasertib (Truqap) targeting AKT, or everolimus (Afinitor) targeting mTORC1—gedatolisib was engineered for multi-node pathway inhibition [cite: 6, 7, 11, 12].
By binding directly to all four class I PI3K catalytic isoforms ($\alpha, \beta, \gamma, \delta$) as well as the kinase domains of mTORC1 and mTORC2, gedatolisib prevents the compensatory pathway crosstalk that drives therapeutic resistance [cite: 6, 7, 11, 12]. In preclinical models, gedatolisib displayed over 300-fold greater potency than single-node PAM inhibitors and was the sole compound tested capable of inducing cytotoxic cell death rather than simple cytostasis [cite: 15].
| Clinical & Operational Attribute | REVTORPYK (gedatolisib) Details | Primary Source Citations |
|---|---|---|
| Primary Indication (FDA Approved) | HR+/HER2- PIK3CA Wild-Type advanced/metastatic breast cancer after prior endocrine therapy | [cite: 1, 4] |
| Dosing Regimen | 180 mg IV weekly (3 weeks on / 1 week off per 28-day cycle) + fulvestrant $\pm$ palbociclib | [cite: 4, 7, 14] |
| Key Efficacy Metric (WT Cohort - Triplet) | Median Progression-Free Survival (mPFS): 9.3 months vs. 2.0 months control (HR: 0.24, 76% risk reduction) | [cite: 4, 7, 13] |
| Key Efficacy Metric (MT Cohort - Triplet) | mPFS: 11.1 months vs. 5.6 months alpelisib (HR: 0.50, 50% risk reduction) | [cite: 4] |
| NCCN Guideline Status | Category 1 Preferred Option | [cite: 1] |
| Primary Safety Considerations | Stomatitis (72% all-grade, 19-22% Grade 3; managed with prophylactic dexamethasone rinse); low hyperglycemia | [cite: 4, 7, 12, 13] |
In August 2026, Celcuity submitted a supplemental New Drug Application (sNDA) to the FDA to expand REVTORPYK's label to include the PIK3CA-mutated cohort [cite: 1, 4]. This filing is supported by Phase 3 VIKTORIA-1 data where the REVTORPYK triplet halved the risk of disease progression or death relative to alpelisib plus fulvestrant (mPFS 11.1 vs 5.6 months) [cite: 1, 4]. Furthermore, Celcuity has expanded its Phase 3 VIKTORIA-2 trial to evaluate gedatolisib combined with a CDK4/6 inhibitor and endocrine therapy as a first-line (1L) treatment for endocrine-sensitive HR+/HER2- advanced breast cancer [cite: 1, 12].
Celcuity’s economic moat relies on intellectual property, regulatory exclusivities, high switching costs embedded in diagnostic workflows, and therapeutic efficacy:
* Intellectual Property (IP) & Proprietary Formulations: Celcuity maintains exclusive worldwide rights to gedatolisib under its licensing agreement with Pfizer [cite: 3, 5, 8]. The IP portfolio encompasses compositions of matter, specific salt forms, combination dosing schedules (e.g., gedatolisib + palbociclib + fulvestrant), and diagnostic selection methods, extending patent protection into the mid-2030s to late-2030s [cite: 8, 15].
* Regulatory Exclusivities & Guidelines Dominance: With FDA approval granted in July 2026, REVTORPYK enjoys New Chemical Entity (NCE) data exclusivity [cite: 1, 4]. Furthermore, the National Comprehensive Cancer Network (NCCN) granted REVTORPYK a Category 1 preferred rating [cite: 1]. In oncology, NCCN Category 1 recommendations drive clinical adoption and compel commercial payors to provide favorable formulary reimbursement coverage [cite: 1].
* CELsignia Ecosystem Integration: The CELsignia platform creates a diagnostic moat by establishing pathway activity profiles that static genomic assays (like FoundationOne or Tempus NGS panels) cannot replicate [cite: 2, 3, 9]. As oncologists integrate live-cell functional testing into diagnostic routines, switching to alternative therapeutics becomes less attractive [cite: 2, 3].
Breast cancer remains the most prevalent cancer among women worldwide, with HR+/HER2- representing approximately 65-70% of all diagnosed cases [cite: 1, 4]. Within the United States, approximately 35,000 to 40,000 patients progress to second-line advanced or metastatic disease each year following initial CDK4/6 inhibitor therapy [cite: 1, 4, 16].
The addressable market splits into two core segments:
* Second-Line (2L+) PIK3CA Wild-Type TAM: Approximately 60-65% of HR+/HER2- patients harbor wild-type PIK3CA tumors [cite: 4, 7]. Historically, this majority sub-population lacked targeted PAM pathway options post-CDK4/6 progression, relying on single-agent endocrine therapy or chemotherapy [cite: 4, 7, 13]. REVTORPYK is the only targeted PAM therapy approved specifically for this segment, unlocking an estimated $2.5B to $3.2B annual market opportunity in the U.S. and Europe [cite: 1, 4].
* Second-Line (2L+) PIK3CA Mutated TAM: Patients with PIK3CA mutations represent 35-40% of the HR+/HER2- population [cite: 6, 17]. Pending sNDA approval, REVTORPYK’s efficacy over alpelisib positions it to capture share in this $1.5B to $2.0B segment [cite: 1, 4].
* First-Line (1L) Expansion TAM (VIKTORIA-2): If successful, moving gedatolisib into first-line treatment triples the addressable patient pool, expanding the global TAM beyond $10B annually [cite: 1, 12].
The PAM pathway targeted oncology space features several multi-national pharmaceutical competitors:
| Feature / Metric | REVTORPYK (gedatolisib) | Piqray (alpelisib) | Itovebi (inavolisib) | Truqap (capivasertib) | Afinitor (everolimus) |
|---|---|---|---|---|---|
| Developer | Celcuity | Novartis | Roche | AstraZeneca | Novartis |
| Target Mechanism | Pan-PI3K + mTORC1/2 | PI3K$\alpha$ Selective | PI3K$\alpha$ + Degrader | AKT1/2/3 | mTORC1 |
| Target Population | HR+/HER2- WT & MT | HR+/HER2- MT Only | HR+/HER2- MT Only | HR+/HER2- Altered | HR+/HER2- All |
| Administration | Intravenous (Weekly) | Oral (Daily) | Oral (Daily) | Oral (Twice Daily) | Oral (Daily) |
| Key Safety Burden | Stomatitis (High) | Hyperglycemia (Severe) | Hyperglycemia (Mod) | Diarrhea, Rash | Stomatitis, Fatigue |
| WT PFS Advantage | 9.3 mos (vs 2.0 mos) | None (Not Approved) | Minimal / N/A | 7.2 mos overall | Modest |
| MT PFS Advantage | 11.1 mos (vs 5.6 mos) | 11.0 mos vs 5.7 mos | 15.0 mos (1L combo) | 7.3 mos vs 3.1 mos | Modest |
| Citations | [cite: 1, 4, 7, 13] | [cite: 4, 6, 12, 17] | [cite: 6, 11, 17] | [cite: 6, 11, 17] | [cite: 6, 7, 11] |
Celcuity is uniquely positioned in the wild-type setting, where competitors lack approval or demonstrate modest efficacy [cite: 4, 6, 7]. In the PIK3CA-mutated segment, REVTORPYK's head-to-head superiority over alpelisib (11.1 months vs. 5.6 months mPFS) provides a clinical advantage, though its weekly IV administration requires patient clinic visits compared to oral drugs [cite: 4, 6, 14].
Celcuity reported its second quarter 2026 financial results on August 13, 2026 [cite: 1, 18]. Because commercial sales of REVTORPYK did not begin until September 30, 2026, Q2 2026 revenue was $0, matching consensus analyst expectations [cite: 4, 18].
| Q2 Financial Metric | Q2 2026 Actual | Q2 2025 Actual | Year-over-Year Change | Wall Street Consensus | Beat / Miss Status |
|---|---|---|---|---|---|
| Total Revenue | $0.00M | $0.00M | N/A | $0.00M | Met Expectations [cite: 18] |
| R&D Expense | $31.08M | $35.04M | -11.3% | N/A | Included in Loss |
| SG&A Expense | $35.04M | $7.59M | +361.7% | N/A | Commercial Ramp |
| GAAP Net Loss | $(82.27)M | $(45.27)M | +81.7% | ~$(65.0)M | Missed Consensus [cite: 1, 18] |
| GAAP EPS | $(1.44) | $(1.04) | -$0.40 | $(1.19) | Missed by $0.25 [cite: 1, 18] |
| Non-GAAP Adj. EPS | $(1.07) | $(0.96) | -$0.11 | ~$(1.05) | Slightly Below [cite: 1] |
| Cash & Investments | $754.04M | $285.10M | +164.5% | N/A | Balance Sheet Expansion [cite: 1] |
For Q2 2026, GAAP net loss widened to $82.27 million (or $1.44 per basic and diluted share), compared to $45.27 million in Q2 2025 [cite: 1]. The EPS loss missed sell-side estimates of $(1.19) per share by $0.25 [cite: 18]. The widened net loss was primarily driven by two key factors:
1. Commercial Infrastructure Expansion: SG&A expenses surged 361.7% year-over-year from $7.59 million to $35.04 million as Celcuity built out its U.S. sales force, patient access programs, medical affairs teams, and marketing collateral ahead of the REVTORPYK launch [cite: 1, 4].
2. Loss on Debt Extinguishment: The company recorded a non-operating, non-cash loss of $11.48 million ($0.21 per share) related to the early repayment and refinancing of its existing term loan facility [cite: 1].
As of June 30, 2026, Celcuity held $182.05 million in cash and cash equivalents and $571.99 million in short-term investments, providing total available liquidity of $754.04 million [cite: 1]. This balance sheet expansion was driven by a $575.0 million convertible note offering completed during the quarter, generating net proceeds of $557.2 million [cite: 1].
The convertible notes carry a principal balance of $753.24 million on the balance sheet [cite: 1]. Current liabilities stood at $86.87 million, including a $50.0 million accrued license milestone payable to Pfizer triggered by FDA approval [cite: 1]. Celcuity’s current cash runway is projected to fully fund commercial launch activities, pay FDA approval milestones to Pfizer, and support the ongoing Phase 3 VIKTORIA-2 trial into 2028 without immediate dilution [cite: 1, 8].
On the Q2 2026 earnings call held August 13, 2026, management emphasized the significance of the July 14 FDA approval, the inclusion of REVTORPYK as a Category 1 preferred agent in NCCN Guidelines, and the August sNDA submission for the PIK3CA-mutated cohort [cite: 1, 4]. Management noted that payor discussions were progressing constructively, with policy coverage expected to materialize throughout Q4 2026 and Q1 2027 [cite: 1, 4].
Following the Q2 2026 announcement, sell-side equity research analysts adjusted price targets, reflecting long-term commercial expectations despite short-term EPS noise [cite: 18, 19]:
* HC Wainwright: Reaffirmed Buy rating, adjusted target to $155.00 USD [cite: 18, 19].
* Guggenheim: Reaffirmed Buy rating, raised price target to $175.00 USD [cite: 18, 19].
* Wells Fargo: Set target at $166.00 USD [cite: 18].
* Craig-Hallum: Reaffirmed Buy rating, set target at $178.00 USD [cite: 18, 19].
The stock experienced short-term price consolidation following earnings due to pre-launch quarterly expenditure levels, but maintained a consensus "Moderate Buy" rating with a median analyst target of $154.25 to $160.00 USD [cite: 18, 19].
To value Celcuity, investors must look past near-term net losses and evaluate the commercial adoption curve of REVTORPYK [cite: 1, 18]. The key valuation drivers include:
* Peak Penetration in PIK3CA Wild-Type Segment: Capturing 25% to 35% of the ~24,000 U.S. 2L WT patients yields ~$600M-$850M in annual revenue, assuming an annual net price of ~$120,000-$150,000 per patient.
* sNDA Expansion in PIK3CA Mutated Segment: Capturing 15% to 25% of the ~14,000 U.S. 2L MT patients adds an additional ~$250M-$450M in annual revenue [cite: 1, 4].
* Pfizer Royalty Obligations: Celcuity owes Pfizer tiered royalties ranging from low-to-mid teens on net sales, alongside up to $330M in remaining milestone payments, which caps terminal operating margins around 28-32% [cite: 3, 8, 15].
| Risk Category | Key Risk Description | Early Warning Indicators | Long-Term Thesis Impact |
|---|---|---|---|
| Execution Risk | Slower-than-expected commercial uptake due to physician preference for oral drugs over weekly IV REVTORPYK infusions [cite: 7, 12, 14]. | Q4 2026 & Q1 2027 initial net revenue underperforming $15M-$20M launch consensus. | Lowers terminal market share in 2L ABC from 30% to <15%. |
| Competitive Risk | Next-generation selective therapies (e.g., allosteric PI3K$\alpha$ inhibitors like zovegalisib) demonstrating equal efficacy with better oral convenience [cite: 17]. | Clinical trial readouts showing superior mPFS (>12 mos) without stomatitis [cite: 17]. | Accelerates market share loss post-2028. |
| Clinical/Safety Risk | High incidence of Grade 3 stomatitis (19-22%) leading to real-world drug discontinuations [cite: 4, 7, 12]. | Real-world treatment drop-out rates exceeding 10% (vs 2.3% in clinical trials) [cite: 7, 17]. | Damaged physician perception; reduced treatment duration. |
| Regulatory Risk | FDA issuing a Complete Response Letter (CRL) or demanding additional safety data for the PIK3CA mutant sNDA [cite: 1, 4]. | Extended PDUFA review dates or FDA requests for extra clinical safety analyses. | Limits total TAM by 35-40%; eliminates head-to-head advantage over alpelisib [cite: 4, 6]. |
| Balance Sheet Risk | Overhanging $753.2M convertible note debt burden requiring future equity dilution if cash flow lags debt maturity [cite: 1]. | Share price remaining below convertible exercise triggers as debt maturity approaches. | Significant equity dilution to honor debt principal obligations [cite: 1]. |
The primary operational risk centres on commercializing an intravenously administered therapy in an outpatient setting dominated by oral targeted agents [cite: 6, 7, 14]. Oncologists and patients may prefer oral regimens (such as capivasertib or inavolisib) due to convenience, despite REVTORPYK’s superior efficacy metrics [cite: 4, 6, 17]. Additionally, managing side effects—specifically Grade 3 stomatitis occurring in up to 22% of patients—requires compliance with prophylactic steroid mouthwash protocols [cite: 4, 7, 12]. If community oncologists fail to enforce prophylactic protocols, elevated discontinuation rates could negatively impact real-world treatment duration [cite: 7, 17].
The oncology market is competitive. While REVTORPYK currently enjoys exclusivity in the PIK3CA wild-type segment, emerging targeted agents like zovegalisib (RLY-2608), an allosteric mutant-selective PI3K$\alpha$ inhibitor granted FDA Breakthrough Therapy designation, represent competitive threats in subsequent years [cite: 4, 17]. If competitor multi-node inhibitors achieve oral administration with reduced toxicity profiles, Celcuity’s market share could erode post-2028 [cite: 6, 17].
Celcuity’s growth trajectory assumes FDA approval of its sNDA for the PIK3CA-mutated cohort [cite: 1, 4]. Any regulatory delay or Complete Response Letter would restrict REVTORPYK to the wild-type population, shaving approximately 35-40% off its addressable market [cite: 4, 7]. On the balance sheet side, the company carries $753.24 million in convertible notes [cite: 1]. If commercial cash flows underperform expectations and the stock price fails to exceed the conversion trigger, Celcuity could face refinancing challenges or dilution upon debt maturity [cite: 1].
Healthcare inflation and reimbursement dynamics present ongoing macro risks. While oncology therapeutics exhibit pricing resilience, pushback from commercial payors, mandatory step-therapy protocols, or potential future drug price negotiations under the U.S. Inflation Reduction Act (IRA) could constrain gross-to-net realization. Furthermore, higher interest rate environments elevate discount rates, reducing the net present value (NPV) of cash flows projected beyond 2028.
To evaluate Celcuity’s potential 5-year equity performance (2026 to 2031), three fundamentals-driven operational scenarios were modeled.
| Scenario Year | 2026 (Current) | 2027 Projected | 2028 Projected | 2029 Projected | 2030 Projected | 2031 (Year 5) |
|---|---|---|---|---|---|---|
| Base Case Share Price | $55.61 USD | $62.00 USD | $70.50 USD | $78.00 USD | $83.00 USD | $87.50 USD |
| High Case Share Price | $55.61 USD | $78.00 USD | $105.00 USD | $132.00 USD | $155.00 USD | $175.56 USD |
| Low Case Share Price | $55.61 USD | $38.00 USD | $25.00 USD | $18.00 USD | $12.50 USD | $9.36 USD |
| Scenario | Revenue / key scale metric in Year 5 | Margin / earnings assumption | Valuation multiple assumption | Current share price | Implied future share price | 5-year total return | Annualized return | Probability |
|---|---|---|---|---|---|---|---|---|
| Base Case | $850.0M USD | 28.0% Net Margin / $3.50 EPS | 25.0x P/E | $55.61 USD | $87.50 USD | +57.3% | +9.5% | 55% |
| High Case | $1,450.0M USD | 32.0% Net Margin / $6.27 EPS | 28.0x P/E | $55.61 USD | $175.56 USD | +215.7% | +25.8% | 25% |
| Low Case | $280.0M USD | 12.0% Net Margin / $0.52 EPS | 18.0x P/E | $55.61 USD | $9.36 USD | -83.2% | -29.8% | 20% |
$\text{Weighted Price Target} = (0.55 \times \$87.50) + (0.25 \times \$175.56) + (0.20 \times \$9.36)$
$\text{Weighted Price Target} = \$48.13 + \$43.89 + \$1.87 = \mathbf{\$93.89\text{ USD}}$
The probability-weighted price target of $93.89 USD indicates an implied 5-year upside potential of +68.8% from the current share price of $55.61 USD [cite: 19].
HIGH ASYMMETRIC UPSIDE
OVERALL BLENDED SCORE: 7.0 / 10
TRANSFORMATIONAL INFLECTION POINT
Celcuity Inc. presents an equity story at the intersection of precision diagnostics and targeted cancer therapeutics [cite: 2, 3, 23]. The July 2026 FDA approval and September 2026 commercial launch of REVTORPYK (gedatolisib) transition the business from a speculative clinical research entity into a commercial-stage oncology firm [cite: 1, 4].
The core investment thesis rests on three pillars:
1. Unrivaled Position in PIK3CA Wild-Type Disease: REVTORPYK addresses an underserved segment comprising 60-65% of all 2L HR+/HER2- metastatic breast cancer patients [cite: 4, 7]. With an NCCN Category 1 preferred rating and a 76% reduction in disease progression risk, REVTORPYK is positioned to capture market share [cite: 1, 4, 13].
2. Head-to-Head Superiority in PIK3CA Mutated Disease: Supported by Phase 3 VIKTORIA-1 cohort data demonstrating an 11.1-month mPFS versus 5.6 months for alpelisib, approval of the pending sNDA would allow REVTORPYK to expand into the remaining 35-40% of the 2L addressable market [cite: 1, 4].
3. Substantial Capital Runway: With $754.04 million in available liquidity, Celcuity possesses the necessary balance sheet strength to execute its commercial ramp, pay Pfizer milestone obligations, and advance Phase 3 1L trials without immediate cash burn risks [cite: 1, 8].
Core upcoming catalysts include initial commercial revenue trajectory readouts in late 2026 and early 2027, the FDA decision on the PIK3CA mutant sNDA label expansion in mid-2027, and Phase 3 VIKTORIA-2 first-line trial data readouts in 2027/2028 [cite: 1, 4, 12].
Key operational risks to monitor include physician adoption rates regarding weekly IV administration versus daily oral alternatives, effective clinical management of stomatitis side effects to prevent drop-outs, and long-term refinancing requirements for its convertible debt balance [cite: 1, 4, 7, 14]. Overall, Celcuity offers a differentiated risk-reward profile backed by clinical data and market opportunity [cite: 1, 4, 13].
ATTRACTIVE ASYMMETRIC OPPORTUNITY
Celcuity’s share price closed at $55.61 USD in mid-October 2026, down approximately 7.8% in recent trading sessions on below-average volume [cite: 19]. The stock is currently trading well below its 50-day simple moving average ($83.62 USD) and its 200-day simple moving average ($102.86 USD), reflecting short-term consolidation and post-approval volatility typical in biotech transitions [cite: 19, 22, 24]. Relative Strength Index (RSI) at 34.32 and short-term stochastics indicate near-term oversold conditions [cite: 25].
Despite short-term technical weakness, the stock maintains fundamental backing, trading at a discount to the sell-side analyst consensus price target of $154.25 USD [cite: 19]. Short-term price action is expected to remain range-bound between support at $50.00 USD and resistance at $78.00 USD until initial Q4 2026 commercial sales figures provide clear evidence of REVTORPYK prescription momentum [cite: 4, 25].
NEAR TERM CONSOLIDATION
View Celcuity Inc. (CELC) stock page
Loading the interactive version of this report…